Appendix 1. Demographics, Clinical Characteristics, and Perioperative Outcomes of Cohort 2: Patients Who Participated in Longitudinal Assessment of Patient Reported Outcomes

	Pre-ERAS (N=67)	ERAS (N=226)	p-value
Age-yr, median (min-max)	58 (32-85)	58 (18-82)	0.52
BMI (kg/m^2)- no.(%)			0.62
< 18.5	1 (1.5)	2 (0.9)	
18.5 – 24.9	16 (23.9)	70 (31.0)	
25.0 – 29.9	24 (35.8)	66 (29.2)	
30.0 – 34.9	10 (14.9)	43 (19.0)	
35.0 – 39.9	8 (11.9)	19 (8.4)	
≥ 40	8 (11.9)	26 (11.5)	
Ethnicity-no.(%)			0.44
Not Hispanic or Latina	55 (82.1)	192 (85.0)	
Hispanic or Latina	12 (17.9)	32 (14.1)	
Not Reported	0 (0.0)	2 (0.9)	
Race-no.(%)			0.01
American Indian / Alaska Native	0 (0.0)	1 (0.4)	
Asian	1 (1.5)	6 (2.6)	
Native Hawaiian or Other Pacific Islander	0 (0.0)	0 (0.0)	
Black or African American	1 (1.5)	30 (13.3)	
White	65 (97.0)	185 (81.9)	
Not Reported	0 (0.0)	4 (1.8)	
ASA Score -no.(%)			0.27
I	0 (0.0)	0 (0.0)	
II	13 (19.4)	26 (11.5)	
III	53 (79.1)	191 (84.5)	

Appendix 1. Demographics, Clinical Characteristics, and Perioperative Outcomes of Cohort 2: Patients Who Participated in Longitudinal Assessment of Patient Reported Outcomes

	Pre-ERAS (N=67)	ERAS (N=226)	p-value
IV	1 (1.5)	5 (2.2)	
Not Reported	0 (0.0)	4 (1.8)	
Charlson Comorbidity Index-no.(%)			0.98
0	5 (7.5)	17 (7.5)	
1 – 2	25 (37.3)	87 (38.5)	
≥ 3	37 (55.2)	122 (54.0)	
Tumor Type-no.(%)			0.13
Malignant – Primary	43 (64.2)	134 (59.3)	
Malignant – Recurrent	10 (14.9)	37 (16.4)	
Neoplasm UMP – Primary	2 (3.0)	18 (8.0)	
Neoplasm UMP – Recurrent	3 (4.5)	1 (0.4)	
Benign	8 (11.9)	34 (15.0)	
None	1 (1.5)	2 (0.9)	
Indication for surgery* -no (%)			
Benign	8 (11.9)	37 (16.4)	0.44
Cervical cancer	1 (1.5)	11 (4.9)	0.31
Ovarian/Fallopian Tube/Primary peritoneal Cancer	42 (62.7)	116 (51.3)	0.12
Uterine cancer (non-sarcoma)	7 (10.5)	37 (16.4)	0.33
Uterine sarcoma	2 (3.0)	9 (4.0)	0.99
Other	1 (2.2)	3 (2.0)	
Chronic Opioid User	2 (3.0)	8 (3.5)	0.99
Prior Chemotherapy	27 (40.3)	98 (43.4)	0.68
Prior Radiation	3 (4.5)	14 (6.2)	0.77

Appendix 1. Demographics, Clinical Characteristics, and Perioperative Outcomes of Cohort 2: Patients Who Participated in Longitudinal Assessment of Patient Reported Outcomes

	Pre-ERAS (N=67)	ERAS (N=226)	p-value
Perioperative outcomes			
Surgical complexity score† -no.(%)			0.78
Low	23 (54.8)	70 (60.3)	
Intermediate	17 (40.5)	41 (35.3)	
High	2 (4.8)	5 (4.3)	
Operating Time (min)-median (min-max)	231 (98-575)	220 (85-840)	0.16
Estimated Blood Loss (ml)-median (min-max)	350 (40-5250)	250 (10-4750)	0.04
Length of Stay (days) -median (min-max)	4 (2-29)	3 (1-25)	< 0.001
Readmission-no.(%)	9 (13.4)	36 (15.9)	0.70
Reoperation -no.(%)	4 (6.0)	5 (2.2)	0.12
Intra-Operative Complications-no.(%)	7 (10.5)	7 (3.1)	0.02
Mortality within 30 Days- no.(%)	0 (0.0)	0 (0.0)	NA
GI Complications within 30 Days-no.(%)	17 (25.4)	57 (25.2)	0.99
Grade 1-2	15 (22.4)	50 (22.1)	0.99
Grade 3-4	2 (3.0)	7 (3.1)	0.99
GU Complications within 30 Days-no.(%)	14 (20.9)	40 (17.7)	0.59
Grade 1-2	13 (19.4)	37 (16.4)	0.58
Grade 3-4	1 (1.5)	3 (1.3)	0.99
CNS Complications within 30 Days-no.(%)	2 (3.0)	1 (0.4)	0.13
Grade 1-2	2 (3.0)	1 (0.4)	0.13
Grade 3-4	0 (0.0)	0 (0.0)	NA
Hematologic Complications within 30 Days-no.(%)	12 (17.9)	26 (11.5)	0.21
Grade 1-2	12 (17.9)	26 (11.5)	0.21
Grade 3-4	0 (0.0)	0 (0.0)	NA

*Patients may have had more than one indication for surgery

†Reported for patients with indication for surgery of ovarian, fallopian tube or primary peritoneal cancer.

Appendix 2. Opioid Use for Cohort 2: Patients Who Participated in Longitudinal Assessment of Patient Reported Outcomes

PACU* + Inpatient Unit

POD 0				
N	67	226		
Median	49.0	7.5	< 0.0001	84.7%
Min – Max	5 – 637.5	0 – 362.3		
POD 1				
N	67	226		
Median	50.0	11.3	< 0.0001	77.4%
Min – Max	0 – 843.0	0 – 529.1		
POD 2				
N	67	218		
Median	25.0	7.5	< 0.0001	70.0%
Min – Max	0 – 752.6	0 – 250.9		
POD 3				
N	63	138		
Median	15.0	7.5	0.0124	50.0%
Min – Max	0 – 481.0	0 – 200.0		
MED per Day				
N	67	226		
Median	38.1	10.0	< 0.0001	73.8%
Min – Max	1.9 – 633.7	0 – 310.6		

*Post-anesthesia care unit

Appendix 3. Longitudinal assessment of daily worst pain during hospital stay. Line with bar represents mean and 95% CI. *P*=.8, value calculated from mixed effect model. ERAS, enhanced recovery after surgery.